STALE?Report written 3 days ago · at $24.84entry levels may be stale — re-check before acting
CAPR
ค่าขนมSMALL CAP
Capricor Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology
$24.84
▲ 0.60%
MCap $1.4B
FDA Advisory Committee meets Jul 29, 2026; PDUFA target action date Aug 22, 2026 for deramiocel (cardiosphere-derived cell therapy) in Duchenne Muscular Dystrophy
BusinessDuchenne Muscular Dystrophy cell therapy · Deramiocel BLA — FDA AdCom Jul 29, PDUFA Aug 22, 2026 · 52-week range $4.30-$40.37 already shows how violently this name moves on trial data
Thesis
Capricor's deramiocel — a cell therapy targeting cardiomyopathy in Duchenne Muscular Dystrophy, a fatal disease with no approved treatment for this specific complication — faces an FDA Advisory Committee vote Jul 29, 2026 followed by a PDUFA decision Aug 22. Analysts rate it Strong Buy with a $53.60 target (+116%). The stock's own 52-week range ($4.30 to $40.37) already shows this name can move 800%+ on trial readouts alone — a positive AdCom vote plus approval is a genuinely two-stage binary catalyst over the next 8 weeks.
📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม
ค่าขนม SPECULATIVE — 2-3% max given a two-stage binary (AdCom Jul 29, PDUFA Aug 22). Approval path → $42-53 (+70% to +115%), full re-rate Moon → $82 (+230%). Negative AdCom crashes to ~$10 (-60%).
85
score / 100 ⓘ
⚡ Catalyst
🏛️ FDA Advisory Committee Vote — Deramiocel4 WEEKS
FDA convenes outside experts to vote on deramiocel's safety/efficacy data for treating cardiomyopathy in DMD. Non-binding, but the FDA usually follows the panel — historically the single biggest catalyst day for a cell/gene therapy stock.
Jul 29, 2026
💊 FDA PDUFA Decision — Deramiocel BLA7 WEEKS
FDA target action date for the deramiocel Biologics License Application. Would be the first approved cell therapy specifically for DMD-related cardiomyopathy — an area of significant unmet need.
Aug 22, 2026
🎯 Entry Point
Entry 1
$24.84
Current price — 4 weeks to AdCom, some time to scale in before the first binaryNow (2-3% max)
Entry 2PREFERRED
$21.11–23
Pre-AdCom de-risking dip zoneIf dips into late Jul
Entry 3
$9.94
Post-negative-AdCom crash zone — only for high-conviction re-entryOnly after a negative AdCom
✅ Take Profit
TP1
Base — positive AdCom + approval, standard commercial ramp
$42.23
+70%
TP2
Bull — clean approval, matches Street consensus target
Pre-AdCom break — sentiment souring ahead of Jul 29, thesis still technically intact
$19.87
-20%
Hard Stop
Negative AdCom vote — this is a gap, not a level; expect the stock to open there, not trade down to it
$9.94
-60%
Risk / Reward
Entry ($24.84) vs TP2 ($53.41), risk sized to the hard-stop gap ($9.94)
1.9 : 1
⚠ Two-stage binary — the Jul 29 AdCom is the first gap risk, Aug 22 PDUFA is the second ⚠️
📅 Estimate Date
FDA Advisory Committee Vote
Non-binding panel vote on deramiocel safety/efficacy — FDA usually follows it
Jul 29, 2026
Vote outcome unknown
FDA PDUFA Decision
Target action date for deramiocel BLA in DMD cardiomyopathy
Aug 22, 2026
Approval favored if AdCom positive
📈 Possible Up % — Scenario Spread
Bear
-60%
$9.94
Base
+70%
$42.23
Bull
+115%
$53.41
Moon
+230%
$81.97
← downsideupside →
🏛️ Fed / Macro Risk — LOW
Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution
Rate Outlook
FDA AdCom and PDUFA events are regulatory, not macro-driven — CAPR will trade on the panel vote and decision, not Fed policy.
Inflation
Rare-disease cell therapy pricing (typically $1M+ per course) is largely insulated from near-term inflation dynamics; payer negotiation matters more.
Sector Impact
LOW direct impact. The current hawkish-Fed backdrop (rate hike priced by October per this week's market read) is a headwind on growth-biotech multiples broadly, but two dated binary events will dominate CAPR's price action through August regardless.
Summary
Fed risk LOW for both binary events. Broader hawkish-Fed sentiment is a secondary drag on the multiple, not the driver of the Jul 29 / Aug 22 moves.
🎯 Analyst Targets
Wall Street price targets vs the current price — cross-check our TP levels
Consensus (10 analysts)
Strong Buy$53.6+116%
current price $24.84
🔍 Similar-Catalyst Comparable Check
Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic
TVTX✅ GoodApr 2026
+34%
in 1 day
Filspari FDA Approval — Expanded FSGS Label
Day-1 move on a rare-disease biologic approval with a broader-than-expected label — same FDA accelerated-approval archetype CAPR is pursuing.
CAPR⚡ Mixedpast 12 months
+838%
in 365 days
CAPR's own 52-week trading range on trial data alone
Stock has traded from a 52-week low of $4.30 to a high of $40.37 purely on trial-data newsflow — direct evidence this specific name is capable of the kind of violent moves a positive AdCom + approval could trigger.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode
Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.
⚠️
Use this stop-loss set (-20% / -60%) only when trading the earnings spot — not for the core holding (use the -20% / -60% set above). If you are holding long-term, follow the core set.
Cell/gene therapy stocks ahead of an AdCom typically see elevated volatility and mixed pre-positioning as the panel briefing documents are released 2-3 days before the vote — those documents themselves can move the stock sharply before the actual vote.
🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +34%
range: +34% to +100%+· Apr 2026 (TVTX); CAPR's own 52-wk history
Travere (TVTX) Filspari FSGS approval: +33.77% day-1. Smaller-cap, less-liquid single-asset biotechs like CAPR (vs. TVTX's larger cap) have historically shown proportionally larger swings — CAPR's own 52-week range ($4.30 to $40.37, an ~840% span) on trial data alone shows this name specifically is prone to outsized moves.
A negative AdCom vote or CRL on a single-asset cell therapy company typically crashes 40-70% same day, as the market re-prices the entire near-term approval probability toward zero.
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio
3% given the two-stage binary structure (AdCom then PDUFA) — two separate gap-risk events in five weeks. Size for the worse of the two outcomes, not the average.
🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding